QBiotics’ Stelfonta (tigilanol tiglate) Receives the US FDA’s Approval as the First Treatment for Non-Metastatic MCT in Dogs

Shots: The approval is based on a study supporting its safety, efficacy in dogs with a measurable cutaneous/ SC MCT on the lower leg and follows the EMA’s MAA granted in early 2020 Stelfonta provides 75% complete tumor resolution after just one injection, and dogs quickly regain pre-treatment QoL. The therapy will be launched in …

QBiotics’ Stelfonta (tigilanol tiglate) Receives the US FDA’s Approval as the First Treatment for Non-Metastatic MCT in Dogs Read More »